Summary of COVID-19 dornase alfa studies
Hide extended summaries
RCT 76 hospitalized COVID-19 patients showing no significant difference with inhaled dornase alfa (DNase I) for resolution of hypoxia or other clinical outcomes.
Apr 2025, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofaf246/8119012, https://c19p.org/akesson
RCT severe COVID-19 patients showing no significant difference in outcomes with dornase alfa.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesdnase
RCT 99 hospitalized COVID-19 patients showing significantly reduced C-reactive protein (CRP) levels and length of hospital stay with nebulized dornase alfa treatment in addition to standard of care (dexamethasone). Authors combine the randomized patients with retrospective patients using matching that does not match for COVID-19 severity. Dornase alfa was associated with a 33% reduction in CRP, a 63% higher chance of discharge at any timepoint up to 35 days, and increased lymphocyte counts. There was a trend towards reduced mortality which was not statistically significant.
Jul 2024, eLife, https://elifesciences.org/articles/87030, https://c19p.org/porter2
1. Åkesson et al., Aerosolized dornase alfa (DNase I) for the treatment of severe respiratory failure in COVID-19: a randomized controlled trial
76 patient dornase alfa late treatment RCT: 11% higher mortality (p=1) and 2% worse recovery (p=0.94).RCT 76 hospitalized COVID-19 patients showing no significant difference with inhaled dornase alfa (DNase I) for resolution of hypoxia or other clinical outcomes.
Apr 2025, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofaf246/8119012, https://c19p.org/akesson
2. Files et al., Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
127 patient dornase alfa late treatment RCT: 9% higher mortality (p=0.78) and 32% worse recovery (p=0.24).RCT severe COVID-19 patients showing no significant difference in outcomes with dornase alfa.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesdnase
3. Porter et al., Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial
99 patient dornase alfa late treatment RCT: 130% higher mortality (p=1) and 10% higher hospital discharge (p=1).RCT 99 hospitalized COVID-19 patients showing significantly reduced C-reactive protein (CRP) levels and length of hospital stay with nebulized dornase alfa treatment in addition to standard of care (dexamethasone). Authors combine the randomized patients with retrospective patients using matching that does not match for COVID-19 severity. Dornase alfa was associated with a 33% reduction in CRP, a 63% higher chance of discharge at any timepoint up to 35 days, and increased lymphocyte counts. There was a trend towards reduced mortality which was not statistically significant.
Jul 2024, eLife, https://elifesciences.org/articles/87030, https://c19p.org/porter2
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.